Tromsø,Norway , January 30[th] 2024 -ArcticZymes Technologies ASA (OSE:AZT) announces the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). SAN HQ GMP fromArcticZymes offers a technically superior solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP,ArcticZymes extends its portfolio to include a GMP-grade nuclease.ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced therapies sector. To streamline the supplier and material qualification process and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves as a superior solution. The inclusion of a US FDA DMF further facilitates regulatory submission. SAN HQ GMP not only offers a technically superior option for enzymatic applications and provides a more straightforward supplier qualification process for customers. By reducing risks and minimizing resource expenditure on external product qualification, the new SAN HQ GMP ensures that clients in the pharmaceutical industry can access the most cutting-edge solution without compromising on compliance. The new SAN HQ GMP will be available for ordering in the second half ofFebruary 2024 . CEOMichael B. Akoh comments: "Today we are announcing the launch of SAN HQ GMP. The novel biomanufacturing enzyme is our first GMP grade enzyme. It is a testament of our commitment to current and future clients by offering a technically superior GMP grade solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. We are fully committed to continue developing new novel GMP grade enzymes to facilitate the manufacturing of advanced therapeutics while having the highest level of compliance." For more information, please contact: CEO,Michael B. Akoh Tel: +46 (0) 70 262 37 15 CFO, Børge Sørvoll Tel: +47 95 29 01 87 ir@arcticzymes.com AboutArcticZymes Technologies ASA ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research,In Vitro Diagnostics (IVD) and biomanufacturing. Listed on theOslo Stock Exchange since 2005 originally under the [AZT] ticker. Its headquarters are based in Tromsø,Norway , at the SIVA Innovation Centre.ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com
Click here for more information
© Oslo Bors ASA, source